Circio Holding ASA (CRNA) 4

[Aaleby]

@Multiple

daytradervenn

Han er ikke tapt bak en stol. Så skal vel ikke se bort fra at det er et lodd tilsvarende som mange andre her inne. Med håp om jackpot.

[Kennyxr]

Har Circio meldt om LBA, eller får vi ikke vite det før event i kveld?

[Pk2k]

De har ikke meldt LBA og dermed er dagens LBA abstrakter, Circio ikke inkludert i.

[MrKirie]

Skjønte ikke helt denne? Ikke at jeg tror de har en LBA, men de slippes jo i kveld, så hvordan skulle vi vite nå om de har fått?

[Pk2k]

Fordi selskaper melder om LBA er akseptert av ASGCT, lenge før abstraktet slippes.

[Kennyxr]

Takker

[Baerntis]

• Tenaya Therapeutics – LBA oral, kliniske data fra RIDGE-1 Fase 1b/2 av TN-401 (PKP2-ARVC) – én-årsdata fra kohort 1 og tidlige kohort 2-data. Hjertegenterapi

• Voyager Therapeutics – LBA oral, VY1706 CNS-penetrerende AAV for Alzheimers, 3-måneds GLP-toksikologistudie i NHP. IND-søknad Q2 2026.

[TekBot]

Circio Holding ASA: Minutes from the annual general meeting 2026

Oslo, 8 May 2026: Circio Holding ASA (the “Company”) held its annual general
meeting today. The meeting was held as a physical meeting at the premises of
Advokatfirmaet Thommessen AS, Ruseløkkveien 38, 0251 Oslo, Norway.
…

Vis børsmeldingen

All resolutions were made in accordance with the proposals from the board of
directors and the nomination committee, including, but not limited to,
approval of the 2025 annual accounts, election of KPMG as the Company’s new
auditor and election of members to the board of directors.

The minutes from the annual general meeting are attached hereto and will also
be made available on the Company’s website
circio.com/investors/general-meetings
(General Meetings – Circio).

This information is subject to disclosure requirements pursuant to Section
5-12 of the Norwegian Securities Trading Act.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Lubor Gaal, CFO
Phone: +34 683 34 3811
Email: lubor.gaal@circio.com

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA
expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression
technology for next generation RNA, DNA and viral therapeutics. The
proprietary circVec platform is based on a modular genetic construct designed
for efficient biogenesis of multifunctional circRNA inside target cells. The
circVec platform has applications in multiple therapeutic settings, including
genetic medicine, cell therapy and chronic disease. It has demonstrated
75-fold increased RNA half-life and up to 50-fold enhanced protein expression
vs. conventional mRNA-based viral and non-viral vector systems, with the
potential to become a new gold-standard gene expression technology. The
circVec R&D activities are being conducted by the wholly owned subsidiary
Circio AB in Stockholm, Sweden.

Kilde

[Frs2904]

Dette innlegget ble rapportert og er midlertidig skjult.

[Kronn]

10kr

[Savepig]

Sterk open!

Edit:
Velkommen til Spillet. Kursen kjøres opp i amatørtimen for å skape litt fomo, så faller den tilbake

[Multiple]

Ikke helt i sync med dagsclose det chartet der?

Det var sprekt i dag. Om det stabiliserer seg på 10 nå så får vi kanskje etter hvert begynne å se på motstanden ved 10.8?

Edit:
Ville ikke stabilisere seg på 10, nei.

Noen som har sett nærmere på handelen under det økte volumet under turen opp til 10.3?
(Om mønsteret taler for robothandel?)

@Savepig
Så det er amatørene som har generert det økte volumet? Hvor var amatørene fra kl 09:00 til kl 09:30?
Finnes det analyser som underbygger amatørtime-myten (at den først timen er dominert av amatørene)?

Jeg tror nok mer profesjonelle tradere og short også benytter den første timen når det presses ned.

[TekBot]

Circio Holding ASA: Issuance of restricted stock units (RSUs) to the board members

Oslo, 11 May 2026: Reference is made to the annual general meeting of Circio
Holding ASA (the “Company”) on 8 May 2026 (the “AGM”) where the election of
members to the board of directors was made according to the proposal by the
…

Vis børsmeldingen

nomination committee.

At the AGM, the board of directors was authorized to extend the Company’s
restricted stock unit (“RSU”) program and to issue RSUs to directors of the
board as an alternative to cash compensation. The RSUs are non-transferable
and each RSU gives the right and obligation to acquire one share in the
Company at a price of NOK 0.60 per share (corresponding to the nominal value
of the shares) subject to satisfaction of the applicable vesting conditions.

If the board members choose to receive the board remuneration in RSUs they
must elect to either (i) receive 100% of the compensation in RSUs, (ii)
receive 1/3 of the compensation in cash and 2/3 in RSUs, or (iii) receive 2/3
of the compensation in cash and 1/3 in RSUs.

The number of RSUs is calculated on the basis of a board remuneration of NOK
575 000 for the chairperson of the board, NOK 350,000 for other board members
and 180,000 for deputy members of the board, divided by the market price of
the Company’s shares calculated as the volume weighted average share price for
the 10 trading days prior to the AGM, on May 8 2026, being NOK 8.7966 per
share.

• Damian Marron, chairman of the board of directors, has resolved to receive
  1/3 of the board remuneration, as determined by the Company’s annual general
  meeting in 2026, in the form of RSUs and the board of directors has resolved
  to issue 21,789 RSUs to Damian Marron. Damian Marron holds 21,789 RSUs, no
  options and 311,863 shares in the Company.

• Diane Mellett, member of the board of directors, has resolved to receive 1/3
  of the board remuneration, as determined by the Company’s annual general
  meeting in 2026, in the form of RSUs and the board of directors has resolved
  to issue 13,263 RSUs to Diane Mellett. Diane Mellett holds 25,933 RSUs, no
  options and 262,258 shares in the Company.

• Thomas Falck, member of the board of directors, has resolved to receive 1/3
  of the board remuneration, as determined by the Company’s annual general
  meeting in 2026, in the form of RSUs and the board of directors has resolved
  to issue 13,263 RSUs to Thomas Falck. Thomas Falck holds 13,263 RSUs, no
  options and 415,535 shares (partly through Sølen AS) in the Company.

Please see the attached notifications of trade for information regarding the
issuance of RSUs to the primary insiders.

This information is subject to the disclosure requirements pursuant to article
19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian
Securities Trading Act.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Lubor Gaal, CFO
Phone: +34 683 34 3811
Email: lubor.gaal@circio.com

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA
expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression
technology for next generation RNA, DNA and viral therapeutics. The
proprietary circVec platform is based on a modular genetic construct designed
for efficient biogenesis of multifunctional circRNA inside target cells. The
circVec platform has applications in multiple therapeutic settings, including
genetic medicine, cell therapy and chronic disease. It has demonstrated
75-fold increased RNA half-life and up to 50-fold enhanced protein expression
vs. conventional mRNA-based viral and non-viral vector systems, with the
potential to become a new gold-standard gene expression technology. The
circVec R&D activities are being conducted by the wholly owned subsidiary
Circio AB in Stockholm, Sweden.

Kilde

[TekBot]

Circio Holding ASA: Registration of share capital increase following exercise of options and settlement of RSUs

Oslo, 11 May 2026: Reference is made to the stock exchange announcement by
Circio Holding ASA (OSE: CRNA) (the “Company”) on 6 May 2026, regarding the
board of directors’ resolution to increase the share capital of the Company in
…

Vis børsmeldingen

connection with the exercise of employee options and the settlement of
restricted stock units (“RSUs”) pursuant to the Company’s long-term incentive
program for its employees and the Company’s program for RSUs for the board
members.

The share capital increase has now been registered with the Norwegian Register
of Business Enterprises (Nw. Foretaksregisteret). The Company’s new share
capital is NOK 142,903,417.20, divided into 238,172,362 shares, each with a
nominal value of NOK 0.60.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Lubor Gaal, CFO
Phone: +34 683 34 3811
Email: lubor.gaal@circio.com

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA
expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression
technology for next generation RNA, DNA and viral therapeutics. The
proprietary circVec platform is based on a modular genetic construct designed
for efficient biogenesis of multifunctional circRNA inside target cells. The
circVec platform has applications in multiple therapeutic settings, including
genetic medicine, cell therapy and chronic disease. It has demonstrated
75-fold increased RNA half-life and up to 50-fold enhanced protein expression
vs. conventional mRNA-based viral and non-viral vector systems, with the
potential to become a new gold-standard gene expression technology. The
circVec R&D activities are being conducted by the wholly owned subsidiary
Circio AB in Stockholm, Sweden.

Kilde

[optimist]

Er det denne meldingen som er kursdrivende?

[BioMed]

10 kr igjen

[TekBot]

Circio Holding ASA: Issuance of restricted stock units (RSUs) to board member

Oslo, 11 May 2026: Reference is made to the annual general meeting of Circio
Holding ASA (the “Company”) on 8 May, 2026 (the “AGM”) where the election of
members to the board of directors was made according to the proposal by the
…

Vis børsmeldingen

nomination committee.

At the AGM, the board of directors was authorized to extend the Company’s
restricted stock unit (“RSU”) program and to issue RSUs to directors of the
board as an alternative to cash compensation. The RSUs are non-transferable
and each RSU gives the right and obligation to acquire one share in the
Company at a price of NOK 0.60 per share (corresponding to the nominal value
of the shares) subject to satisfaction of the applicable vesting conditions.

If the board members choose to receive the board remuneration in RSUs they
must elect to either (i) receive 100% of the compensation in RSUs, (ii)
receive 1/3 of the compensation in cash and 2/3 in RSUs, or (iii) receive 2/3
of the compensation in cash and 1/3 in RSUs.

The number of RSUs is calculated on the basis of a board remuneration of NOK
575 000 for the chairperson of the board, NOK 350,000 for other board members
and 180,000 for deputy members of the board, divided by the market price of
the Company’s shares calculated as the volume weighted average share price for
the 10 trading days prior to the AGM, on 8 May 2026, being NOK 8.7966 per
share.

• Robert Burns, deputy member of the board of directors, has resolved to
  receive 1/3 of the board remuneration, as determined by the Company’s annual
  general meeting in 2026, in the form of RSUs and the board of directors has
  resolved to issue 6,821 RSUs to Robert Burns. Robert Burns holds 6,821 RSUs,
  no options and 100,000 shares in the Company.

Please see the attached notifications of trade for information regarding the
issuance of RSUs to the primary insiders.

This information is subject to the disclosure requirements pursuant to article
19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian
Securities Trading Act.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Lubor Gaal, CFO
Phone: +34 683 34 3811
Email: lubor.gaal@circio.com

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA
expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression
technology for next generation RNA, DNA and viral therapeutics. The
proprietary circVec platform is based on a modular genetic construct designed
for efficient biogenesis of multifunctional circRNA inside target cells. The
circVec platform has applications in multiple therapeutic settings, including
genetic medicine, cell therapy and chronic disease. It has demonstrated
75-fold increased RNA half-life and up to 50-fold enhanced protein expression
vs. conventional mRNA-based viral and non-viral vector systems, with the
potential to become a new gold-standard gene expression technology. The
circVec R&D activities are being conducted by the wholly owned subsidiary
Circio AB in Stockholm, Sweden.

Kilde

[Multiple]

Når man har forsonet seg med tanken om at den kanskje skal ned og teste 8 igjen , så går den heller til 10 .

Men det er bedre med litt volum enn med de aksjene som står i stampe med omsetning på noen hundre kroner.

Ingen synlig shortendring siden 4 mai. Klarer ikke algoritmene helt å bestemme seg?

[skeptiker]

Det kan være best for aksjene uten å være best for tegningsrettene.

[aol]

Neighbors in collaboration: New partnerships emerge at Novum Labs